ScoreWhy is Halozyme Therapeutics, Inc. ?
1
High Management Efficiency with a high ROCE of 59.50%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 23.90
3
Healthy long term growth as Operating profit has grown by an annual rate 41.43%
4
Flat results in Mar 26
- ROCE(HY) Lowest at 99.4%
- RAW MATERIAL COST(Y) Grown by 5.26% (YoY)
- CASH AND EQV(HY) Lowest at USD 461.44 MM
5
With ROCE of 39.63%, it has a very expensive valuation with a 4.51 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 31.86%, its profits have risen by 50.8% ; the PEG ratio of the company is 0.2
6
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Halozyme Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Halozyme Therapeutics, Inc. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Halozyme Therapeutics, Inc.
31.86%
1.14
31.70%
S&P 500
22.24%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
39.16%
EBIT Growth (5y)
41.43%
EBIT to Interest (avg)
23.90
Debt to EBITDA (avg)
1.57
Net Debt to Equity (avg)
1.57
Sales to Capital Employed (avg)
0.54
Tax Ratio
19.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
59.50%
ROE (avg)
203.20%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
149.00
EV to EBIT
11.37
EV to EBITDA
10.27
EV to Capital Employed
4.51
EV to Sales
6.65
PEG Ratio
0.17
Dividend Yield
NA
ROCE (Latest)
39.63%
ROE (Latest)
1371.85%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 677.42 MM
NET SALES(HY)
At USD 828.48 MM has Grown at 47.19%
INVENTORY TURNOVER RATIO(HY)
Highest at 2.17 times
-9What is not working for the Company
ROCE(HY)
Lowest at 99.4%
RAW MATERIAL COST(Y)
Grown by 5.26% (YoY
CASH AND EQV(HY)
Lowest at USD 461.44 MM
DEBT-EQUITY RATIO
(HY)
Highest at 831.38 %
INTEREST(Q)
Highest at USD 5.51 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 57.94 %
Here's what is working for Halozyme Therapeutics, Inc.
Operating Cash Flow
Highest at USD 677.42 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 828.48 MM has Grown at 47.19%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 2.17 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Depreciation
Highest at USD 33.73 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Depreciation
At USD 33.73 MM has Grown at 26.44%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (USD MM)
Here's what is not working for Halozyme Therapeutics, Inc.
Interest
At USD 5.51 MM has Grown at 12.16%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Interest
Highest at USD 5.51 MM
in the last five periods and Increased by 12.16% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Profit Margin
Lowest at 57.94 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Cash and Eqv
Lowest at USD 461.44 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 831.38 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 5.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
